|
Vaccine Detail
L. donovani LD31 Protein Vaccine |
Vaccine Information |
- Vaccine Name: L. donovani LD31 Protein Vaccine
- Target Pathogen: Leishmania donovani
- Target Disease: Visceral leishmaniasis
- Vaccine Ontology ID: VO_0004179
- Type: Subunit vaccine
- Status: Research
- F1-ATPase
gene engineering:
- Type: Recombinant protein preparation
- Description:
- Detailed Gene Information: Click Here.
- Adjuvant:
- Immunization Route: Intraperitoneal injection (i.p.)
|
Host Response |
Mouse Response
- Host Strain: BALB/c
- Vaccination Protocol: Mice were immunized by intraperitoneal injections of 2.5 µg purified proteins in PBS or incorporated in liposome in a total volume of 200 µl. Animals receiving PBS or empty liposomes served as controls. Mice were boosted two times at 2-week intervals (Bhowmick and Ali, 2009).
- Challenge Protocol: Ten days after the final immunization the mice were challenged with 2.5×10^7 freshly transformed stationary-phase promastigotes in 200 µl PBS injected intravenously via the tail vein (Bhowmick and Ali, 2009).
- Efficacy: Liposomal LD31 (ATP synthase alpha chain) reduced parasite burden by 74%-77% (Bhowmick and Ali, 2009).
|
References |
Bhowmick and Ali, 2009: Bhowmick S, Ali N. Identification of novel Leishmania donovani antigens that help define correlates of vaccine-mediated protection in visceral leishmaniasis. PloS one. 2009; 4(6); e5820. [PubMed: 19503834].
|
|